Pharmaceutical companies and research centers around the world are developing vaccines against kovid 19 and conducting extensive clinical trials of candidates worldwide, involving tens of thousands of volunteers, Reuters reported.
Photo: depositphotos / valuavitaly
On November 18, the American pharmaceutical company “Pfizer” and its German partner “BioNT” announced that the final phase of clinical trials of the vaccine had confirmed 95% effectiveness, the highest among the remaining candidates.
Another modern American company announced on November 16 that the final phase of clinical trials in a large number of volunteers was 94.5 percent effective.
The Russian “Sputnik V” vaccine, the first in the world to be registered, showed a 92% efficacy in the final phase of clinical trials, and these results were announced on 11 November.
AstraZeneca reported on Monday that the coronavirus vaccine being developed by scientists at Oxford University could be 90 percent effective without serious side effects.
The company “Johnson & Johnson” has announced that they are on track to find out the results of the vaccine test this year.
In the initial trials, the infection rate of volunteers was low, but the fall was later reduced, with new cases increasing worldwide.
The results of the final phase of the “Pfizer” clinical trials show that among the 43,000 volunteers, 170.15 had been confirmed to have the coronavirus.
“Moderna” reported 95 cases of infection among participants in the final phase of clinical trials, including Russia 20 and “AstraZeneca” 131.
The World Health Organization is calling for clinical trials to confirm at least 70 percent effectiveness of the vaccine, the U.S. Drug Enforcement Administration 50 percent, and the European Medicines Agency said it can support lower vaccine effectiveness.
“Pfizer” and “BioNT” plan to apply for emergency permits in the United States in the coming days.
“Moderna” also plans to apply for an emergency permit in the coming weeks. That should happen in the second half of November, as soon as two months have elapsed since vaccine safety data was obtained among half of those who participated in the test, as mandated by the U.S. Food and Drug Administration.
This means that it is unlikely that the Food and Drug Administration will take a decision before December.
AstraZeneca announced on Monday that it will immediately prepare reports on the results of tests to obtain conditional or prior authorization from the world’s competent authorities.
Authorities around the world will review vaccine data as soon as it becomes available, and it is still unclear when it will happen or when the agencies will make a decision.
China began in July to include workers from sectors at high risk of coronary heart disease. Hundreds of thousands of people in this country have been vaccinated so far.
At least four Chinese vaccines are still a long way from the final stages of clinical trials, including those being developed by CNBG, Kansino Bajologiks and Sinova Bajot.
On November 18, “Sinova” announced that the mid-stage of clinical trials had elicited an immune response in volunteers, but that the level of antibodies to the virus was lower than in people who cured kovid 19.
The CNBG will publish the results of the initial phase of clinical trials this month.
“Sputnik V” received about 10,000 Russian citizens who are at risk of contracting coronaviruses.